Viridian Therapeutics Inc (NASDAQ:VRDN) stock is up 11.1% to trade at $15.75 today, and earlier traded as high as $16.35, after the biotech company's eye disorder treatment met the main goal of a late-stage study. VRDN is on track for its best single-session gain of 2024. Despite today's breakout, the shares are still 28% lower year to date, and momentum has fallen short of its 200- day moving average. A short squeeze could keep the wind at the equity's back though; short interest fell 7.3% in the two most ...